drugset / Trial / NCT07152288

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

NCT07152288

Phase 1 Recruiting 24 enrolled Haisco Pharmaceutical Group Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HSK39297 in subjects with mild to moderate hepatic impairment and normal hepatic function

Timeline

Start
2025-05-29
Primary completion
2025-09
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK39297 Unknown Oral